JNJ

229.16

+0.48%↑

ABBV

214.96

+3.03%↑

UNH

391.95

+1.01%↑

AZN

185.58

+0.81%↑

NVS

150.75

+0.83%↑

JNJ

229.16

+0.48%↑

ABBV

214.96

+3.03%↑

UNH

391.95

+1.01%↑

AZN

185.58

+0.81%↑

NVS

150.75

+0.83%↑

JNJ

229.16

+0.48%↑

ABBV

214.96

+3.03%↑

UNH

391.95

+1.01%↑

AZN

185.58

+0.81%↑

NVS

150.75

+0.83%↑

JNJ

229.16

+0.48%↑

ABBV

214.96

+3.03%↑

UNH

391.95

+1.01%↑

AZN

185.58

+0.81%↑

NVS

150.75

+0.83%↑

JNJ

229.16

+0.48%↑

ABBV

214.96

+3.03%↑

UNH

391.95

+1.01%↑

AZN

185.58

+0.81%↑

NVS

150.75

+0.83%↑

Home・Aktien・Eli Lilly and Co.

Eli Lilly and Co.

Open

BrancheGesundheitswesen

1,010.92 2.17

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

980

Max

1021.02

Schlüsselkennzahlen
By Trading Economics
Einkommen	758M 7.4B
Verkäufe	507M 20B
KGV Branchendurchschnitt	34.327 51.415
EPS	8.55
Dividendenrendite	0.66
Gewinnspanne	37.355
Angestellte	50,000
EBITDA	971M 9.4B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+27.81% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	0.66% 2.34%
Nächstes Ergebnis	5. Aug. 2026
Nächste Dividendenausschüttung	10. Juni 2026
Nächstes Ex-Dividendendatum	14. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	87B 862B
Vorheriger Eröffnungskurs	1008.75
Vorheriger Schlusskurs	1010.92

Nachrichtenstimmung

By Acuity

22%

78%

48 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

N/A / 884.54 Unterstützung & Widerstand

Eli Lilly and Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Eli Lilly and Co. Prognose

Kursziel

By TipRanks

27.81% Vorteil

12-Monats-Prognose

Durchschnitt 1,262.85 USD 27.81%

Hoch 1,500 USD

Tief 850 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eli Lilly and Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

22 ratings

Buy

Halten

Sell

Basierend auf 22 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Eli Lilly and Co. – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 884.54Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

48 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.